Thanks to the resurgence in the precious metals market, New Gold Inc (NYSEAMERICAN: NGD) is back to building on its blistering run. On a year-to-date basis, NGD stock has gained about 266%. Over the trailing five sessions, the security is up more than 10%, thereby showing little signs of buyer exhaustion. Indeed, a rare quantitative signal that flashed in New Gold's price chart indicates that even more upside is possible.Adding to the enthusiasm, New Gold is scheduled to release its earnings report on Feb. ...

Key Takeaways IonQ posted 222% YoY revenue growth and set a world-record two-qubit gate performance.D-Wave's revenues rose 235% YTD with strong bookings for its Advantage2 annealing system.Both IONQ and QBTS benefit from government funding, enterprise partnerships and strategic expansions.The global quantum computing market remains early-stage but is growing rapidly. Recent industry forecasts put total quantum computing revenues at around $1.08 billion in 2026, up from roughly $0.8 billion in 2025, with lon ...

Key Takeaways NVIDIA is highlighted as a top S&P 500 pick due to its strong profitability and a 53% net income ratio.Micron earns a spot in the screen with a 28.2% net income ratio, reflecting solid earnings relative to sales. Seagate Technology, with 17.9% net income ratio, qualifies, signals cost control and revenue strength.As we near 2026, investors should seek companies that generate strong returns after covering all operating and non-operating expenses. Therefore, it’s wise to invest in a profitable c ...

Approvals expand Amneal’s biosimilars portfolioCompany expects to commercialize six biosimilars across eight presentations by 2027 BRIDGEWATER, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, today announced that the U.S. Food and Drug Administration (FDA) has approved its Biologics Licensing Applications (BLAs) for Boncresa™ (denosumab-mobz), a biosi ...

FLORHAM PARK, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today announced the closing of its previously disclosed financing transactions with Philip A. Barach, co-founder and former president of DoubleLine Capital LP. At the closing, Celularity received $10.00 million in gross proceeds. The transaction structure provides for the potential availability of up to an addition ...

Prediction markets let users buy and sell contracts tied to the outcomes of real-world events, ranging from elections and economic data to sports and policy decisions, effectively turning investors' forecasts into tradable markets. Supporters say the prices can reflect collective expectations more accurately than polls or forecasts, while critics argue the products blur the line between financial markets and betting, drawing growing scrutiny from regulators. Coinbase said on Monday it will buy prediction ma ...

PHILADELPHIA, PA, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Five Below, Inc. (NASDAQ: FIVE), the trend-right, high-quality extreme-value retailer for the kid and the kid in all of us, today announced that management is currently scheduled to host a fireside chat at the 2026 ICR Conference in Orlando, Florida, on Monday, January 12, 2026, at 10:00 a.m. Eastern Time. The fireside chat will be webcast live at http://investor.fivebelow.com/. An archived replay will be available two hours after the conclusion of the liv ...

Key Takeaways Gold and silver are on track for their strongest annual gains since 1979, powered by demand for safe-haven assets amid tariff turmoil, falling interest rates, and major buying by central banks.Copper's record run reflects surging demand worldwide from EV, AI infrastructure, and renewable energy construction projects. Investors continue to buy up metals, driving the prices of gold and silver to new highs. Gold hit $4,460 per ounce Monday, an all-time high in a year that's already seen it s ...

All right, Tom. So, 2023 we turned in 24%. 2024 we turned in 23%.Pretty good this year, too. 17%. Next year, we fill in the blank with what sounds reasonable to you.>> Um, I think it's still possible to have a double digit year. There have been 12 times in the last 100 years where markets posted three years of 20% gains. This year hasn't finished yet.um globally half the time markets do even better in the following year. So I think next year is a year where the debate's going to be is the bull cycle over or ...

Looking into the current session, HCA Healthcare Inc. (NYSE:HCA) shares are trading at $472.00, after a 0.21% decrease. Over the past month, the stock decreased by 8.48%, but over the past year, it actually spiked by 54.99%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. Comparing HCA Healthcare P/E Against Its PeersThe P/E ratio measures the current share price to the company ...